Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU firms facing new requirements for orphan drug designation

This article was originally published in Scrip

Executive Summary

Companies developing products for rare diseases in the EU could be facing changes to the requirements for gaining orphan drug designation, after the European Commission announced that it planned to review the criteria for showing that a new product has a "significant benefit" over existing treatments.

You may also be interested in...



Roche Fined For Anticompetitive Behavior In Romania

Roche plans to appeal against a penalty imposed by the Romanian competition authorities for implementing strategies that were said to delay the entry of competing biosimilar and generic products. 

EU Parallel Trade: The ‘Most Effective Savings Tool Available’

The EU association representing parallel traders says cheaper parallel imports are vital in keeping medicines affordable for member states.

EMA Suspends Leo’s Actinic Keratosis Drug Picato

The latest drug safety actions by the European Medicines Agency affect products for dermatological use and vaginal atrophy.

Topics

UsernamePublicRestriction

Register

SC028483

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel